Tonix Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights
GlobeNewswire · 3天前
Tonix Pharmaceuticals Q2 EPS $(0.23) Up From $(0.95) YoY
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(0.23) per share. This is a 75.79 percent increase over losses of $(0.95) per share from the same period last year.
Benzinga · 3天前
Tonix Pharma on go with study of TNX-102 SL in alcohol use disorder
The FDA has signed off on a Phase 2 proof-of-concept study evaluating Tonix Pharmaceuticals' (TNXP +6.0%) TNX-102 SL for the treatment of alcohol use disor
seekingalpha · 08/06 18:43
Tonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use Disorder
NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New D
Tonix Pharmaceuticals (TNXP) regains compliance with the minimum bid price requirement for continued listing on the NASDAQ Global Market. On August 3, the
seekingalpha · 08/04 20:17
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement